20 November 2023
20 November 2023
Clinical Trials Arena explores how post-marketing studies are still led by academia while commercial sponsors spearhead early clinical research.
Oxurion’s diabetic macular oedema drug failed to meet its primary endpoint in the Phase IIb trial.
The newest data comes from further analysis of the Phase III INDIGO trial of vorasidenib, which met its endpoints in June 2023.
The report published by the Association of the British Pharmaceutical Industry found that UK trials rose from 394 in 2021 to 411 in 2022.
Gilde Healthcare now manages over $2.8bn in assets across Europe and North America, much of which is held in young companies.
Data after 24 months demonstrated the balloon, which releases the anti-restenotic drug sirolimus, met trial's primary endpoints.
The primary endpoint of the Phase II clinical trial is progression free survival.
The AB-1005 gene therapy is being analysed to treat mild to moderate Parkinson’s disease.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
